Linking uterine ultrasound features to adenomyosis symptoms
Official title: Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms (MUSA 3)
Run by Swiss GO Trial Group · NCT07397715 · Data updated 2026-11-12
This project will see if specific ultrasound signs in the uterine muscle match the symptoms reported by pre- and perimenopausal women who come for a gynecologic ultrasound.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 1000 (estimated) |
| Sponsor | Swiss GO Trial Group Research network |
| Locations | 5 sites (Leuven and 4 other locations) |
| Status | Recruiting |
| Started | March 15, 2024 |
| Main results expected | February 1, 2028 |
| Study ends | February 1, 2029 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT07397715 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are consenting pre- and perimenopausal women presenting for a gynecologic ultrasound, whether they have symptoms or not, who are not pregnant and agree to fill out symptom and bleeding questionnaires.
✕Probably not a fit
Women who are postmenopausal, currently pregnant, have recent relevant pelvic surgery, known uterine/cervical malignancy, or other excluded comorbidities are not eligible and are unlikely to benefit from this imaging-focused project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, cross-sectional observational study that enrolls consecutive pre- and perimenopausal women presenting for gynecologic ultrasound, both with and without symptoms. Participants have one visit during which a standardized transvaginal ultrasound using MUSA-defined features is performed and they complete questionnaires on bleeding and pain. Investigators will compare ultrasound features (direct and indirect signs of adenomyosis) with reported symptoms and aim to develop a standardized reporting system to grade disease severity. There are no interventions and data are collected only at the single visit.
Why it matters
Potential benefit: If successful, the work could improve noninvasive diagnosis and create a standardized ultrasound reporting system to better match imaging findings with patient symptoms.
How similar studies have gone: Previous work and the MUSA consensus support using ultrasound features to diagnose adenomyosis, but links between those imaging signs and symptom severity and a validated severity reporting system remain incompletely established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women of pre- and perimenopausal age presenting for gynaecologic ultrasound exam giving voluntary informed written consent. * Symptomatic and asymptomatic women * Patients with hormonal contraceptives and Hormone Replacement Therapy (HRT) can be included, but information will be noted. Exclusion Criteria: * Missing written consent (study consent) * Any serious underlying medical, psychiatric or psychological condition, which may interfere with the patient's capacity of discernment. * Postmenopausal women * Pregnancy * History of pelvic urogynaecologic surgery (TVT, mesh surgery, etc.) * Malignancy or premalignancy of uterus/cervix * Prior myomectomy for FIGO 3-6 fibroids * Patients with coagulation disorders under current anticoagulation medication * Prior history of diagnosed intraabdominal adhesions (surgery) * Prior diagnosis of pelvic congestion syndrome * Psychiatric disease precluding a reliable estimation of pain * Prior surgery or treatment for deep infiltrating endometriosis * Acute other symptoms: * Urinary symptoms (dysuria, urgency, grade III stress incontinence) * Acute of chronic pelvic infection (cervicitis, endometritis, salpingitis, frozen pelvis) * Ovarian lesions * Sonographic signs of deep infiltrating endometriosis (DIE) * Intracavitary pathology (Fibroid 0-2, polyp, adhesions) * Retained products of conception * \>3 small fibroids below 2 cm in largest diameter FIGO 3-8 (i.e. the presence of three fibroids below 2cm is NOT considered an exclusion criterion) * Presence of any fibroid \>2cm.
Where it's running
-
UZ Leuven
Leuven, Belgium Recruiting -
Medical University of Silesia
Sosnowiec, Poland Recruiting -
Hospital Universitari Dexeus
Barcelona, Spain Recruiting -
University Hospital Basel
Basel, Canton of Basel-City, Switzerland Recruiting -
Kantonsspital Winterthur
Winterthur, Switzerland Recruiting
Study contacts
- Principal investigator: Gwendolin Manegold-Brauer, Prof. Dr. — Deputy Head Physician, Obstetrics and Prenatal Medicine
- Study coordinator: Gwendolin Manegold-Brauer, Prof. Dr.
- Email: gwendolin.manegold-brauer@usb.ch
- Phone: +41612659046
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
-
AI into Ultrasound Diagnostics in Reproductive Medicine
Researchers are testing AI tools that analyze transvaginal ultrasound images to help detect endometriosis, adenomyosis, uterine masses, and pregnancy-related receptivity in women aged 18-45.
-
Deep muscle relaxation and a low-residue diet to improve the surgical view during vNOTES hysterectomy
This trial tests whether a preoperative low-residue diet and deeper muscle relaxation help doctors see better during a vaginally performed hysterectomy for benign conditions.
-
Current medical approaches for managing adenomyosis
The study will see which treatments women aged 20–50 with adenomyosis receive and how long they continue them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.